---
categories: 
- Database
- Release
date: 2023-12-07
title: Database release
---
Added entries:
- (FDA) _PIK3CA_ and _AKT_ somatic variants and _PTEN_ loss of function variants and sensitivity to capivasertib in combination with fulvestrant for patients with breast cancer.
- (FDA) _ROS1_ rearrangements and sensitivity to repotrectinib in patients with nsclc.

Revised entries:
- (FDA) _ERBB2_ amplification and sensitivity to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma received an updated indication from the FDA. 
- (FDA) _NTRK1/2/3_ rearrangements and sensitivity to larotrectinib were changed from translocation to fusion rearrangement type.
- _EGFR_ p.L858R entries now all contain information for exon and rsid values
- _ABL1_ p.T315I entries were revised to have consistent exon and rsid values
- _NRAS_ p.G12C entries now include an rsid
- The OncoTree terms and codes were swapped for _ATK1_ missense variants and p.E17K and sensitivity to MK-2206 in breast cancer and _ATM_ knockdowns in colorectal cancer

Removed entries:
- (Clinical evidence) _PTEN_ deletions and resistance to pembrolizumab in uterine leimyoma (Peng et al. 2016) had a duplicate entry in the knowledge base, which has been removed.